Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The March 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Indus Biotech.
Pre-EMP-tive strike against GBM Michael J. Haas doi:10.1038/scibx.2014.389 UCLA researchers have treated glioblastoma in mice by inhibiting EMP2. The findings open up a new indication for spinout Paganini, which has a mAb against the target in development for triple-negative breast cancer. Full Text | PDF
Positioning properdin Kai-Jye Lou doi:10.1038/scibx.2014.390 Researchers at the University of Leicester have shown that a recombinant properdin produced in collaboration with The Medicines Co. has markedly higher antibacterial activity than the native protein. The researchers are now working to improve the recombinant protein's activity and homogeneity. Full Text | PDF
Catastrophic vacuolization Tracey Baas doi:10.1038/scibx.2014.391 Karolinska Institute scientists have attacked glioblastoma multiforme by inducing an unconventional cell death pathway involving catastrophic vacuolization. The team identified a small molecule that prolonged survival in mouse GBM, but a combination approach with a conventional anticancer agent will likely be necessary in the clinic. Full Text | PDF
Toxic assets C. Simone Fishburn doi:10.1038/scibx.2014.392 A tool for in vivo detection of liver toxicity could represent a substantial improvement over in vitro methods. The litmus test for the Stanford University inventors will be to show that the nanoparticle-based method can detect toxicity in compounds that previously eluded standard analysis and later failed in the clinic. Full Text | PDF
Epithelial membrane protein 2 (EMP2) doi:10.1038/scibx.2014.393 Patient sample and mouse studies suggest targeting EMP2 could be used to treat glioblastoma multiforme (GBM). Full Text | PDF
Anoctamin 1 calcium activated chloride channel (ANO1) doi:10.1038/scibx.2014.394 In vitro studies suggest compounds that promote ANO1 degradation, as opposed to ANO1 antagonists, could be useful for treating cancer. Full Text | PDF
Not applicable doi:10.1038/scibx.2014.395 In vitro and mouse studies suggest the rheumatoid arthritis (RA) drug Ridauraauranofin could be used to treat CLL. Full Text | PDF
Splice variant v6 of CD44 (CD44v6); phosphoinositide 3-kinase (PI3K) doi:10.1038/scibx.2014.396 In vitro and mouse studies suggest inhibiting CD44v6 and PI3K could be useful for preventing metastasis in colorectal cancer. Full Text | PDF
Jagged 1 (JAG1); notch 2 (NOTCH2); fibroblast growth factor 4 (FGF4); fibroblast growth factor receptor 1 (FGFR1; CD331) doi:10.1038/scibx.2014.397 Cell culture and mouse studies suggest inhibiting JAG1-NOTCH2 or FGF4-FGFR1 signaling could help treat Burkitt lymphoma. Full Text | PDF
Ubiquitin specific peptidase 1 (USP1); WD repeat domain 48 (WDR48; UAF1) doi:10.1038/scibx.2014.398 Cell-based studies suggest inhibiting the USP1-UAF1 complex could help increase NSCLC and bone cancer sensitivity to platinum-based chemotherapies. Full Text | PDF
Sterol O-aceyltransferase 1 (SOAT1; ACAT1) doi:10.1038/scibx.2014.399 Studies in patient samples, mice and cell culture suggest inhibiting ACAT1 prevents cholesteryl ester (CE) synthesis and could help treat prostate cancer. Full Text | PDF
Peroxisome proliferation–activated receptor-γ (PPARG; PPARγ); myeloid-lymphoma or mixed-lineage 5 (MLL5); 5′-3′ exoribonuclease 2 (XRN2) doi:10.1038/scibx.2014.400 In vitro and mouse studies suggest activating genes involved in the plasma cholesterol–lowering response could help treat atherosclerosis. Full Text | PDF
Thrombin (factor IIa; F2) doi:10.1038/scibx.2014.401 In vitro studies suggest an allosteric thrombin inhibitor could prevent blood clots and thrombosis. Full Text | PDF
Farnesoid X receptor (FXR; NR1H4) doi:10.1038/scibx.2014.402 Mouse studies suggest FXR is required to mediate the effects of vertical sleeve gastrectomy—a type of bariatric surgery—on obesity. Full Text | PDF
Synoviolin (SYVN1; HRD1) doi:10.1038/scibx.2014.403 Studies in human samples and mice suggest inhibiting HRD1 could help treat liver cirrhosis. Full Text | PDF
Pannexin 1 (PANX1) doi:10.1038/scibx.2014.404 In vitro studies suggest avoiding PANX1 inhibition could prevent the toxic side effects of some quinolone antibiotics. Full Text | PDF
Peroxisome proliferation–activated receptor-γ (PPARG; PPARγ) doi:10.1038/scibx.2014.405 Studies in mice and human samples suggest combining PPARγ agonists with antimalarial therapy could improve outcomes in cerebral malaria. Full Text | PDF
Properdin doi:10.1038/scibx.2014.406 Mouse studies suggest recombinant properdin could help protect against bacterial meningitis and pneumonia. Full Text | PDF
Leukotriene A4 hydrolase (LTA4H) doi:10.1038/scibx.2014.407 Structure-based design studies led to an LTA4H inhibitor that could be useful as a lead for new anti-inflammatory agents. Full Text | PDF
Nanoparticles for in vivo detection of drug-induced hepatotoxicity doi:10.1038/scibx.2014.408 Mouse studies suggest semiconducting polymer nanoparticles (SPNs) could be used for real-time in vivo monitoring of drug-induced hepatotoxicity. Full Text | PDF
Polymerized antibody–tagged magnetic beads for isolation of circulating tumor cells (CTCs) doi:10.1038/scibx.2014.409 Magnetic beads tagged with polymerized antibodies or antibody-like molecules could help capture CTCs for cancer research purposes. Full Text | PDF
Protein misfolding cyclic amplification (PMCA) technique to create α-synuclein (SNCA) aggregates for drug screening doi:10.1038/scibx.2014.410 In vitro studies suggest SNCA aggregates formed using PMCA could be used to screen antiaggregating agents for Parkinson's disease (PD). Full Text | PDF
Mice with human innate immune cells doi:10.1038/scibx.2014.411 Humanized mice with functional human innate immune cells could be used as models to study cancer in the presence of an intact human immune system. Full Text | PDF
Mouse model of amyotrophic lateral sclerosis (ALS) caused by partial loss of TAR DNA binding protein 43 (Tdp-43; Tardbp) function doi:10.1038/scibx.2014.412 Mice with partial loss of Tdp-43 function could be useful as models to study and screen for new compounds to treat ALS. Full Text | PDF
Pituitary ablation of estrogen receptor expression as a mouse model for ovarian cancer doi:10.1038/scibx.2014.413 A genetic mouse model for estrogen-dependent ovarian cancer could be used to study disease progression and evaluate therapeutic candidates. Full Text | PDF
Carbonic anhydrase IX (CAIX)-targeted small molecule–drug conjugates doi:10.1038/scibx.2014.414 CAIX-targeted small molecule conjugates could be useful for imaging and treating cancer. Full Text | PDF
Crystal structure of purinergic receptor P2Y G protein–coupled 12 (P2RY12; P2Y12) bound to an antagonist doi:10.1038/scibx.2014.415 In vitro structural studies of P2RY12 bound to an antagonist could aid antithrombotic drug design. Full Text | PDF
Enhanced antigen-specific T cell activation using nanoscale artificial antigen-presenting cells (aAPCs) in a magnetic field doi:10.1038/scibx.2014.416 In vitro and mouse studies suggest magnetic-field culturing methods could increase activation of antigen-specific T cells by nanoscale aAPCs. Full Text | PDF
Small molecule inhibitors of microRNA processing doi:10.1038/scibx.2014.417 An in vitro screening system could be used to identify small molecule inhibitors of miRNAs. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment